Sales of Trimeris' AIDS Drug in North America Surge

Sales of its AIDS drug Fuzeon surged 23 percent in North America in the second quarter,

Trimeris

(Nasdaq: TRMS) said Wednesday.

U.S. and Canada sales hit $31.1 million for the quarter ending June 30.

Global sales totaled $57.2 million, up 6 percent for the same time period in 2005. The increase came despite the fact that Brazil, which makes bulk purchases of Fuzeon on an intermittent basis, did not make a purchase in the quarter, according to a Trimeris spokesperson.

Sales are recorded by Roche, Trimeris' partner in production of Fuzeon.